Details for Patent: 8,859,562
✉ Email this page to a colleague
Which drugs does patent 8,859,562 protect, and when does it expire?
Patent 8,859,562 protects LYNPARZA, ZEJULA, AKEEGA, and RUBRACA, and is included in six NDAs.
This patent has fifty-nine patent family members in twenty-four countries.
Summary for Patent: 8,859,562
Title: | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Abstract: | The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination. |
Inventor(s): | Helleday; Thomas (Stockholm, SE) |
Assignee: | The University of Sheffield (Sheffield, GB) |
Application Number: | 10/555,507 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,859,562 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,859,562
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | LYNPARZA | olaparib | CAPSULE;ORAL | 206162-001 | Dec 19, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR | ⤷ Try a Trial | ||||
Glaxosmithkline | ZEJULA | niraparib tosylate | CAPSULE;ORAL | 208447-001 | Mar 27, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS | ⤷ Try a Trial | ||||
Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-001 | Aug 11, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION | ⤷ Try a Trial | ||||
Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-002 | Aug 11, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,859,562
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
United Kingdom | 0317466.1 | Jul 25, 2003 |
PCT Information | |||
PCT Filed | July 23, 2004 | PCT Application Number: | PCT/GB2004/003235 |
PCT Publication Date: | February 10, 2005 | PCT Publication Number: | WO2005/012524 |
International Family Members for US Patent 8,859,562
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 454893 | ⤷ Try a Trial | |||
Austria | 516353 | ⤷ Try a Trial | |||
Australia | 2004261462 | ⤷ Try a Trial | |||
Australia | 2004261779 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |